Muscle loss on tirzepatide vs retatrutide is one of the most searched questions about these two Eli Lilly drugs, along with which one causes more weight loss. Tirzepatide is approved; retatrutide is still in trials.

Tirzepatide (Mounjaro, Zepbound) is FDA approved and acts on GIP and GLP-1 receptors. Retatrutide is not approved and adds the glucagon receptor[1]. In separate trials, the top doses lost −25.0% at 80 weeks[2] and −20.9% at 72 weeks[3]. The head-to-head trial, TRIUMPH-5[4], has not reported and has no body-composition outcome. No study shows that either drug spares muscle better. The only retatrutide head-to-head so far is against semaglutide, in type 2 diabetes.
Retatrutide: human RCTs (phase 3). Not approved; Lilly plans to submit to FDA in Q1 2027.
Tirzepatide: approved drug with an FDA label.
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Developer | Eli Lilly (LY3437943; nicknames "reta", "GLP-3") | Eli Lilly (brands Mounjaro, Zepbound; nickname "tirz") |
| How it works | GIP, GLP-1 and glucagon receptors[1] | GIP and GLP-1 receptors |
| Status | Not approved. Lilly plans to submit to FDA in Q1 2027 (Lilly press releases, 2026-07-23 and 2026-09-29). FDA says it cannot be compounded[5] | FDA approved (Mounjaro for type 2 diabetes; Zepbound for weight management) |
| Main weight result (top dose) | −25.0% vs −3.9% placebo at 80 weeks, treatment-regimen[2] | −20.9% vs −3.1% placebo at 72 weeks[3] |
| Half-life | About 6 days[6] | Label check pending. |
| Stopped for side effects | 4.1–11.3% vs 4.9% placebo in TRIUMPH-1 (Lilly press release, 2026-05-21) | 4.3–7.1% vs 2.6% placebo in SURMOUNT-1[3] |
| Signature side effects | Dysesthesia (skin burning or tingling); heart rate rose with dose[7] | Per-arm rates are not included here. |
| Body-composition data | Phase 2 substudy in type 2 diabetes, 36 weeks[8] | SURMOUNT-1 substudy, 72 weeks[9] |
Cross-trial table. TRIUMPH-1 and SURMOUNT-1 differ in length (80 vs 72 weeks) and population, so one row is not a head-to-head result.
Separate trials: not a head-to-head comparison
Scale: 0–30%
Treatment-regimen estimand, n = 2,339 adults with obesity, no diabetes[2].
Scale: 0–30%
Adults with obesity, no diabetes[3]. Separate trial from the chart above: different length and estimand reporting. Trial arms, not dose advice; milligrams do not convert between these drugs.
What TRIUMPH-5 will and won't tell us. TRIUMPH-5[4] randomises about 800 people with obesity to retatrutide or tirzepatide. Its primary outcome is percent weight change at week 80. Secondary outcomes cover BMI, waist, lipids, blood pressure, HbA1c, fasting insulin and quality of life. It has no DXA or other body-composition outcome, so it will not answer the muscle question. When we checked the registry on 2026-11-17 it was active and not recruiting, primary completion was estimated for November 2026, and no results were posted.
The only retatrutide head-to-head so far is against semaglutide. In TRANSCEND-T2D-2, an open-label 80-week trial in type 2 diabetes, weight fell −19.5% and −20.9% on retatrutide 9 and 12 mg vs −9.4% on Ozempic 2 mg (efficacy estimand; Lilly press release, 2026-10-28)[10]. It is not yet peer-reviewed. For context, tirzepatide beat semaglutide head-to-head in SURMOUNT-5: −20.2% vs −13.7% at 72 weeks[11].
No study has measured muscle or lean mass on retatrutide and tirzepatide in the same trial. Each drug has one DXA substudy, in different people, over different lengths of time.
Separate trials: not a head-to-head comparison
Scale: 0–40%
n = 160[9]. About 75% of the weight lost was fat and 25% lean mass, a similar split in the tirzepatide and placebo groups.
Scale: 0–40%
103 completers[8]. The authors describe the lean-mass share of weight lost as "similar to other obesity treatments"; we have not found a per-arm lean figure to chart.
So the honest answer to "does retatrutide preserve muscle better than tirzepatide?" is that no data exist to say. The two substudies differ in population (with and without type 2 diabetes), length (36 vs 72 weeks) and what they report. A claim that retatrutide is "muscle-sparing" has no source.
| Event | Retatrutide 4 / 9 / 12 mg | Placebo | Tirzepatide (SURMOUNT-1) | Placebo |
|---|---|---|---|---|
| Nausea | 28.6 / 38.4 / 42.4% | 14.8% | Data are not included here. | - |
| Vomiting | 10.6 / 22.8 / 25.3% | 4.8% | Data are not included here. | - |
| Dysesthesia (skin burning or tingling) | 5.1 / 12.3 / 12.5% | 0.9% | Data are not included here. | - |
| Stopped for side effects | 4.1 / 6.9 / 11.3% | 4.9% | 4.3–7.1%[3] | 2.6% |
Each drug against its own trial's placebo. Retatrutide figures from Lilly's TRIUMPH-1 release (2026-05-21); paper:[2].
In retatrutide's phase 2 trial, heart rate rose with dose, peaked at week 24 and then declined[7]. Across phase 3, dysesthesia ranged from 4.5% to 20.9% by arm; details are on the retatrutide page.
No trial has measured appetite or "food noise" on the two drugs head-to-head. Online threads often say tirzepatide is better for appetite and retatrutide for metabolism. That is what people report, not a trial finding.
One study analysed Reddit posts from 7,823 people describing non-approved retatrutide use: 17.1% reported increased appetite[12]. These are self-reports about products whose identity and dose could not be checked, so they say nothing reliable about the trial drug.
Switching. No trial has tested moving from tirzepatide to retatrutide. Retatrutide's phase 3 trials excluded people who had used weight-loss drugs in the 90 days before screening[13], and there is no official milligram conversion between the two. The retatrutide page covers how the trials started people on the drug.
Together. No trial has given tirzepatide and retatrutide together.
ClinicalTrials.gov, searched 2026-11-17
| Claim | Verdict | What the source says |
|---|---|---|
| Retatrutide beat tirzepatide by 23% in a phase 3 head-to-head (a ranking comparison page) | False | TRIUMPH-5 had posted no results on 2026-11-17[4] |
| Retatrutide trials started at 0.25 mg, given IV (same page) | False | Phase 3 trials started at 2 mg, under the skin (Lilly press releases on TRIUMPH-1 and TRIUMPH-4) |
| Retatrutide preserves muscle better than tirzepatide | No source | No trial has compared body composition on the two drugs |
| Retatrutide and semaglutide have never been tested head-to-head (search summary) | Out of date | TRANSCEND-T2D-2 reported on 2026-10-28[10] |
SURMOUNT-1 published: tirzepatide −15.0% to −20.9% at 72 weeks.
Jastreboff et al., NEJM 2022[3] Human randomised trialSURMOUNT-5 published: tirzepatide −20.2% vs semaglutide −13.7% at 72 weeks.
NEJM 2025[11] Human randomised trialRetatrutide's first phase 3 readout (TRIUMPH-4, knee osteoarthritis).
Lilly press release; paper NEJM 2026[14] Company press releaseTRIUMPH-2 and TRIUMPH-3 toplines; Lilly says it plans to submit retatrutide to FDA in Q1 2027.
Lilly press release[15] Company press releaseFDA states retatrutide cannot be used in compounding under federal law.
FDA statement on unapproved GLP-1 drugs[5] RegulatorTRANSCEND-T2D-2: first retatrutide head-to-head (vs semaglutide), topline.
Lilly press release[10] Company press releaseTRIUMPH-5 (retatrutide vs tirzepatide) estimated primary completion. No results yet.
ClinicalTrials.gov[4] Trial registryWe will update this page when TRIUMPH-5 reports. FDA has also sent warning letters to firms selling or repackaging retatrutide, including a January 2026 letter to a facility that repackaged tirzepatide and retatrutide (FDA warning letter to GenoGenix LLC, 2026-01-20).
Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.
The trial that will answer this, TRIUMPH-5, has not reported. In separate trials, top doses lost −25.0% at 80 weeks on retatrutide and −20.9% at 72 weeks on tirzepatide, which is not a head-to-head result.
No data show that. Each drug has one DXA substudy in different people over different lengths, and TRIUMPH-5 does not measure body composition[4].
No retatrutide trial has measured muscle growth, strength or function. Its body-composition substudy measured fat and lean mass by DXA, and lean mass is not the same as muscle[8].
Yes: TRIUMPH-5. On 2026-11-17 the registry estimated primary completion for November 2026 and showed no results[4]. Lilly has not announced a readout date.
In TRANSCEND-T2D-2, people with type 2 diabetes lost −20.9% on retatrutide 12 mg vs −9.4% on Ozempic 2 mg at 80 weeks (Lilly press release, 2026-10-28)[10]. The trial was open-label and is not yet peer-reviewed.
No trial has compared appetite or "food noise" on the two drugs. Online comparisons are personal reports.
No trial has tested the two together (ClinicalTrials.gov, searched 2026-11-17).
No. Lilly has published no milligram conversion, and milligrams of different molecules are not equivalent. See the retatrutide page for what the trials did.